CA2145681A1 - Method for antogonizing inositol 1,4,5-triphosphate - Google Patents

Method for antogonizing inositol 1,4,5-triphosphate

Info

Publication number
CA2145681A1
CA2145681A1 CA002145681A CA2145681A CA2145681A1 CA 2145681 A1 CA2145681 A1 CA 2145681A1 CA 002145681 A CA002145681 A CA 002145681A CA 2145681 A CA2145681 A CA 2145681A CA 2145681 A1 CA2145681 A1 CA 2145681A1
Authority
CA
Canada
Prior art keywords
inositol
triphosphate
calcium
release
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002145681A
Other languages
English (en)
French (fr)
Inventor
Kenneth A. Stauderman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2145681A1 publication Critical patent/CA2145681A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002145681A 1992-09-28 1993-08-30 Method for antogonizing inositol 1,4,5-triphosphate Abandoned CA2145681A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95239392A 1992-09-28 1992-09-28
US07/952,393 1992-09-28

Publications (1)

Publication Number Publication Date
CA2145681A1 true CA2145681A1 (en) 1994-04-14

Family

ID=25492868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002145681A Abandoned CA2145681A1 (en) 1992-09-28 1993-08-30 Method for antogonizing inositol 1,4,5-triphosphate

Country Status (13)

Country Link
EP (1) EP0661982A1 (zh)
JP (1) JPH08502068A (zh)
KR (1) KR950703347A (zh)
AU (1) AU670962B2 (zh)
CA (1) CA2145681A1 (zh)
HU (1) HUT70192A (zh)
IL (1) IL107066A (zh)
MX (1) MX9305933A (zh)
NO (1) NO951163L (zh)
NZ (1) NZ256178A (zh)
TW (1) TW260663B (zh)
WO (1) WO1994007507A1 (zh)
ZA (1) ZA936978B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2978995A (en) * 1994-06-30 1996-01-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for treating cell proliferative disorders by modulating signal transduction
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US6083920A (en) * 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6133319A (en) * 1996-06-27 2000-10-17 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0915651A4 (en) 1996-06-27 2001-10-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
ATE358486T1 (de) * 2000-11-09 2007-04-15 Contrimmune Biotechnology Inc Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektion
JP2014531425A (ja) 2011-09-02 2014-11-27 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 肥満の代謝異常を治療するためのＣａＭＫＩＩ、ＩＰ３Ｒ、カルシニューリン、ｐ３８、およびＭＫ２／３阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB781479A (en) * 1953-08-27 1957-08-21 Ciba Ltd New polyureas and process for making them
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers

Also Published As

Publication number Publication date
IL107066A0 (en) 1993-12-28
ZA936978B (en) 1994-04-18
NO951163D0 (no) 1995-03-27
JPH08502068A (ja) 1996-03-05
WO1994007507A1 (en) 1994-04-14
MX9305933A (es) 1994-04-29
AU4841793A (en) 1994-04-26
HU9500891D0 (en) 1995-05-29
EP0661982A1 (en) 1995-07-12
HUT70192A (en) 1995-09-28
IL107066A (en) 1998-01-04
TW260663B (zh) 1995-10-21
KR950703347A (ko) 1995-09-20
AU670962B2 (en) 1996-08-08
NO951163L (no) 1995-03-27
NZ256178A (en) 1997-03-24

Similar Documents

Publication Publication Date Title
Silveira et al. Putative M2 muscarinic receptors of rat heart have high affinity for organophosphorus anticholinesterases
Akera Membrane Adenosinetriphosphatase: A Digitalis Receptor? The enzyme is a good model for receptor binding studies because of its known functional correlates.
LeRoy et al. Pharmacokinetic study of cis-dichlorodiammineplatinum (II)(DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic milieu
TWI268923B (en) N6 heterocyclic 8-modified adenosine derivatives
US5204329A (en) Treatment of organ transplantation rejection
CA2145681A1 (en) Method for antogonizing inositol 1,4,5-triphosphate
CZ20012340A3 (cs) Kombinace inhibitorů transportu kyčelní ľlučové kyseliny a proteinových inhibitorů cholesteryl-esterového přenosu pro kardiovaskulární indikace
EP1320364A1 (en) The use of histamine h3-receptor inverse agonists for the control of appetite and treatment of obesity
Mikkelsen et al. Verapamil and nifedipine inhibition of contractions induced by potassium and noradrenaline in human mesenteric arteries and veins
Itokawa et al. Renal and skeletal lesions in experimental cadmium poisoning of rats. Histology and renal function
JPH07502737A (ja) 複素環式化合物およびそれらの製法並びに使用
US5763492A (en) Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
NZ337400A (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo
EP0393494A3 (en) Bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
Łażewska et al. Alkyl derivatives of 1, 3, 5-triazine as histamine H4 receptor ligands
Harris et al. Effects of dihydropyridine derivatives and anticonvulsant drugs on [3H] nitrendipine binding and calcium and sodium fluxes in brain
WO1993023035A2 (en) Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
BRAUN et al. The attenuation of epinephrine-dependent adenylate cyclase by adenosine and the characteristics of the adenosine stimulatory and inhibitory sites
Yamashita et al. NZ-105, a new 1, 4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta
WO2002050080A1 (en) Small molecules useful in the treatment of inflammatory disease
JP2003512607A (ja) ムスカリン受容体のアロステリック部位
Lee et al. Potent enhancement of [3H] nitrendipine binding in rat cerebral cortical and cardiac homogenates: a putative mechanism for the action of MDL 12,330 A.
US20110251227A1 (en) Analgesic agents
Zhang Muscarinic receptors in developing rat colon
DE3904795C2 (de) Pharmazeutisches Präparat und dessen Verwendung

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 19990518